HTA Regulation: JCA scope extends to orphan medicines
European CommissionLegislation milestone
High impact in 425 days
Medicines designated as orphan medicinal products become subject to EU joint clinical assessment. Sponsors should plan JCA dossiers and PICO scoping alongside the MAA.
Add to Google Calendar Subscribe to all dates (iCal)
Get the outcome, not just the date
VigiEye subscribers get related guidance and regulatory changes summarised by AI, filtered to their products and markets. The free weekly email lists this date when it is two weeks out.
Free weekly "EU regulatory week ahead" email. Or start monitoring.
Related upcoming dates
Dates are taken from the official source above. Agencies occasionally reschedule; confirm on the source before acting.